PABPC4L | Poly(A) binding protein, cytoplasmic 4-like | | | | | | Tissue enhanced |
PCDH10 | Protocadherin 10 | Predicted membrane proteins
| | | | | Tissue enhanced |
PCDH12 | Protocadherin 12 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PDPN | Podoplanin | Predicted membrane proteins
| | | | | Tissue enhanced |
PEG10 | Paternally expressed 10 | | | | | | Tissue enhanced |
PEG3 | Paternally expressed 3 | Transcription factors
| | | | | Tissue enhanced |
PGF | Placental growth factor | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PHLDA2 | Pleckstrin homology-like domain, family A, member 2 | | | | | | Tissue enhanced |
PITX2 | Paired-like homeodomain 2 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
PKIB | Protein kinase (cAMP-dependent, catalytic) inhibitor beta | | | | | | Tissue enhanced |
PRLR | Prolactin receptor | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PTGES | Prostaglandin E synthase | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
REN | Renin | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
RP11-169F17.1 | Protein LOC400655 | Predicted membrane proteins
| | | | | Tissue enhanced |
RSPO2 | R-spondin 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
S100P | S100 calcium binding protein P | Plasma proteins
| | | | | Tissue enhanced |
SERPINE1 | Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SH3TC2 | SH3 domain and tetratricopeptide repeats 2 | Disease related genes
| | | | | Tissue enhanced |
SLC19A3 | Solute carrier family 19 (thiamine transporter), member 3 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC2A1 | Solute carrier family 2 (facilitated glucose transporter), member 1 | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SOX14 | SRY (sex determining region Y)-box 14 | Transcription factors
| | | | | Tissue enhanced |
SP6 | Sp6 transcription factor | Transcription factors
| | | | | Tissue enhanced |
SPTLC3 | Serine palmitoyltransferase, long chain base subunit 3 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
STC2 | Stanniocalcin 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
STRA6 | Stimulated by retinoic acid 6 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
STS | Steroid sulfatase (microsomal), isozyme S | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TBX4 | T-box 4 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
TCHH | Trichohyalin | Cytoskeleton related proteins Plasma proteins
| | | | | Tissue enhanced |
TENM3 | Teneurin transmembrane protein 3 | Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
TFAP2A | Transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) | Disease related genes Transcription factors
| | | | | Tissue enhanced |
TFAP2C | Transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma) | Transcription factors
| | | | | Tissue enhanced |
THSD7A | Thrombospondin, type I, domain containing 7A | Predicted membrane proteins
| | | | | Tissue enhanced |
TINAGL1 | Tubulointerstitial nephritis antigen-like 1 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
TPRXL | Tetra-peptide repeat homeobox-like | | | | | | Tissue enhanced |
TREML2 | Triggering receptor expressed on myeloid cells-like 2 | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
TRIM40 | Tripartite motif containing 40 | | | | | | Tissue enhanced |
TRPC6 | Transient receptor potential cation channel, subfamily C, member 6 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
TUSC3 | Tumor suppressor candidate 3 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
UBASH3B | Ubiquitin associated and SH3 domain containing B | Enzymes
| | | | | Tissue enhanced |
USP27X | Ubiquitin specific peptidase 27, X-linked | Enzymes
| | | | | Tissue enhanced |
VGLL3 | Vestigial like 3 (Drosophila) | | | | | | Tissue enhanced |
VSTM5 | V-set and transmembrane domain containing 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
WFDC1 | WAP four-disulfide core domain 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
WNT6 | Wingless-type MMTV integration site family, member 6 | Predicted secreted proteins
| | | | | Tissue enhanced |
WNT7A | Wingless-type MMTV integration site family, member 7A | Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ZSCAN4 | Zinc finger and SCAN domain containing 4 | Transcription factors
| | | | | Tissue enhanced |